BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37868825)

  • 21. Development of a five-gene signature as a novel prognostic marker in ovarian cancer.
    Wang R; Ye XH; Zhao XL; Liu JL; Zhang CY
    Neoplasma; 2019 May; 66(3):343-349. PubMed ID: 30569721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer.
    Ding B; Yan W; Shen S; Meng D; Chen X; Wang S; Shen Y
    Cancer Control; 2023; 30():10732748231168756. PubMed ID: 37078136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.
    Cui M; Xia Q; Zhang X; Yan W; Meng D; Xie S; Shen S; Jin H; Wang S
    Front Genet; 2021; 12():688207. PubMed ID: 35087563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer.
    Wu M; Gu S; Yang J; Zhao Y; Sheng J; Cheng S; Xu S; Wu Y; Ma M; Luo X; Zhang H; Wang Y; Zhao A
    BMC Cancer; 2024 Feb; 24(1):267. PubMed ID: 38408960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer.
    Jiang H; Awuti G; Guo X
    ACS Omega; 2023 Sep; 8(36):33017-33031. PubMed ID: 37720747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
    Zheng P; Li N; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.
    Zhang W; Liu T; Jiang L; Chen J; Li Q; Wang J
    Front Genet; 2022; 13():1001239. PubMed ID: 36425071
    [No Abstract]   [Full Text] [Related]  

  • 31. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
    Duan Y; Xu X
    Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism-related gene vaccines and immune infiltration in ovarian cancer: A novel risk score model of machine learning.
    Fu Y; Huang Z; Huang J; Xiong J; Liu H; Wan X
    J Gene Med; 2024 Jan; 26(1):e3568. PubMed ID: 37455244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An EMT-based gene signature enhances the clinical understanding and prognostic prediction of patients with ovarian cancers.
    Li QJ; Wu ZL; Wang J; Jiang J; Lin B
    J Ovarian Res; 2023 Mar; 16(1):51. PubMed ID: 36907877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients.
    Zheng J; Guo J; Zhu L; Zhou Y; Tong J
    J Ovarian Res; 2021 Sep; 14(1):124. PubMed ID: 34560889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing of programmed cell death gene signature for predicting ovarian cancer prognosis and treatment response.
    Lian X; Liu B; Wang C; Wang S; Zhuang Y; Li X
    Front Endocrinol (Lausanne); 2023; 14():1182776. PubMed ID: 37342266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma.
    Chen X; Sun B; Chen Y; Xiao Y; Song Y; Liu S; Peng C
    Transl Oncol; 2024 May; 43():101905. PubMed ID: 38387388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Features, Prognostic Value, and Cancer Immune Interactions of Angiogenesis-Related Genes in Ovarian Cancer.
    Ji Y; Ge Q; Zhang W; Qu P
    Reprod Sci; 2023 May; 30(5):1637-1650. PubMed ID: 36471217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer.
    Gao Y; Shi H; Zhao H; Yao M; He Y; Jiang M; Li J; Li Z; Su S; Liu T; Yin C; Liao X; Yue W
    Clin Transl Med; 2023 Sep; 13(9):e1416. PubMed ID: 37712139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signatures of tumor-associated macrophages correlate with treatment response in ovarian cancer patients.
    Gao Y; Qi Y; Shen Y; Zhang Y; Wang D; Su M; Liu X; Wang A; Zhang W; He C; Yang J; Dai M; Wang H; Cai H
    Aging (Albany NY); 2024 Jan; 16(1):207-225. PubMed ID: 38175687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.